TuisNB3 • FRA
add
Neurocrine Biosciences Inc
Vorige sluiting
€109,00
Dagwisseling
€110,00 - €110,00
Jaarwisseling
€100,85 - €147,45
Markkapitalisasie
12,15 mjd USD
Gemiddelde volume
31,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 627,70 m | 21,84% |
Bedryfskoste | 301,80 m | 37,87% |
Netto inkomste | 103,10 m | -30,20% |
Netto winsgrens | 16,43 | -42,69% |
Wins per aandeel | 1,69 | 9,74% |
EBITDA | 138,10 m | -11,47% |
Effektiewe belastingkoers | 36,59% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,08 mjd | 4,31% |
Totale bates | 3,72 mjd | 14,37% |
Totale aanspreeklikheid | 1,13 mjd | 10,75% |
Totale ekwiteit | 2,59 mjd | — |
Uitstaande aandele | 99,70 m | — |
Prys om te bespreek | 4,18 | — |
Opbrengs op bates | 9,03% | — |
Opbrengs op kapitaal | 10,75% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 103,10 m | -30,20% |
Kontant van bedrywe | 242,50 m | 96,36% |
Kontant van beleggings | -68,30 m | 66,15% |
Kontant van finansiering | -290,00 m | -919,21% |
Netto kontantverandering | -116,10 m | -172,54% |
Beskikbare kontantvloei | 220,28 m | 138,04% |
Meer oor
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Gestig
1992
Hoofkwartier
Webwerf
Werknemers
1 800
